In vitrodrug–drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition
- 1 May 2008
- journal article
- research article
- Published by Taylor & Francis Ltd in Xenobiotica
- Vol. 38 (5), 496-510
- https://doi.org/10.1080/00498250801956350
Abstract
1. The potential for drug–drug interactions with febuxostat was examined in the following three in vitro systems: the characteristics of the binding of febuxostat to human plasma proteins; identification of the cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) enzymes participating in the metabolism of febuxostat; and the potential inhibitory effects of febuxostat on typical CYP reactions. 2. The results have shown that the presence of ibuprofen or warfarin did not change the plasma protein binding of febuxostat, and that febuxostat did not influence the plasma protein binding of ibuprofen or warfarin. These results indicate that there is little possibility that febuxostat causes a drug–drug interaction by binding to albumin. 3. The UGT 1 and 2 families were involved in the glucuronidation, and several CYPs participated in the metabolism of febuxostat, suggesting that there is little possibility that the blood concentration of febuxostat varies widely even if febuxostat is concomitantly administered with drugs that inhibit CYP or UGT enzyme. Examination of the inhibitory effect of febuxostat on CYP enzymes suggests that febuxostat minimally inhibits the activities of any CYP. 4. The results demonstrate that febuxostat is a novel anti-hyperuricaemia drug with low drug–drug interaction potential in clinical use.Keywords
This publication has 22 references indexed in Scilit:
- Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and GoutNew England Journal of Medicine, 2005
- Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenaseLife Sciences, 2005
- Effect of febuxostat on pharmacokinetics of desipramine, a CYP2D6 substrate, in healthy subjectsClinical Pharmacology & Therapeutics, 2005
- An Extremely Potent Inhibitor of Xanthine OxidoreductaseJournal of Biological Chemistry, 2003
- The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism*†Drug Metabolism Reviews, 2001
- Human UDP-Glucuronosyltransferases: Metabolism, Expression, and DiseaseAnnual Review of Pharmacology and Toxicology, 2000
- Nomenclature for human CYP2D6 allelesPharmacogenetics, 1996
- Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodentsEuropean Journal of Pharmacology, 1993
- Verapamil plasma binding: Relationship to α1-acid glycoprotein and drug efficacyClinical Pharmacology & Therapeutics, 1983
- The location of drug binding sites in human serum albuminBiochemical Pharmacology, 1981